Search XTNT
Xtant Medical Holdings, Inc.
NYSE · CIK 1453593
Last close0.34
Daily change-0.01 (-2.86%)
10 Years gain-97.62%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
XTNT · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
64.6Momentum
66.6Acceleration
67.7Confidence
91.0Annual Revenue16
Quarterly Revenue53
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality19.5 / 25
Capital Efficiency7.0 / 20
Balance Sheet13.8 / 15
Shareholder Economics3.7 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.5334 percentage points.
Operating leverageOperating margin improved by 3.318 percentage points.
ROIC expansionROIC improved by 3.8882 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 2.1463%.
Key Metrics
Revenue Growth TTM-5.12%OK
Revenue CAGR 3Y32.2%OK
Gross Margin63.58%OK
Operating Margin-4.38%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-7.52%OK
Incremental Operating Margin 3Y0.25%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-2.15%OK
SBC / Revenue2.65%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $133.93M | $84.27M | $7.28M | $12.55M | $10.16M | 62.92% | 5.44% | 7.59% | 9.98% | 150.04M |
| 2025 FY Dec 31, 2024 | $117.27M | $68.22M | -$12.07M | -$11.90M | -$16.01M | 58.17% | -10.3% | -13.65% | -15.69% | 133.67M |
| 2024 FY Dec 31, 2023 | $91.30M | $55.47M | -$10.16M | -$9.52M | -$10.97M | 60.75% | -11.13% | -12.02% | -18.58% | 126.79M |
| 2023 FY Dec 31, 2022 | $57.97M | $32.14M | -$6.76M | -$5.34M | -$7.11M | 55.44% | -11.65% | -12.26% | -22.24% | 94.09M |
| 2022 FY Dec 31, 2021 | $55.26M | $32.49M | -$3.85M | $439,000.00 | -$1.68M | 58.79% | -6.97% | -3.03% | -11.4% | 85.46M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $112.58M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-036981, 0001493152-25-021512 |
| Revenue Growth TTM | -5.12% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-036981, 0001493152-25-021512 |
| Revenue CAGR 3Y | 32.2% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-013792 |
| Revenue CAGR 5Y | 20.22% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-013792 |
| Gross Profit CAGR 3Y | 37.9% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-013792 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-036981, 0001493152-25-021512 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 63.58% | Gross Profit / Revenue | OK | 0001493152-26-036981, 0001493152-25-021512 |
| Operating Margin | -4.38% | Operating Income / Revenue | OK | 0001493152-26-036981, 0001493152-25-021512 |
| ROIC | -7.52% | NOPAT / Average Invested Capital | OK | 0001493152-26-036981, 0001493152-25-021512 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-036981 |
| Current Ratio | 2.16x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.35x | (Cash + Short-term Investments) / Total Debt | OK | 0001493152-26-036981 |
| SBC / Revenue | 2.65% | SBC / Revenue | OK | 0001493152-26-036981, 0001493152-26-022604 |